Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesAnimal models for Ebola and Marburg virus infectionsVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesEffective post-exposure treatment of Ebola infectionNucleocapsid formation and RNA synthesis of Marburg virus is dependent on two coiled coil motifs in the nucleoproteinCurrent ebola vaccinesDurability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primatesEbola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent UpdatesPre-symptomatic diagnosis and treatment of filovirus diseasesMouse models for filovirus infectionsMarburg Virus Reverse Genetics SystemsDelayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus MacaquesVaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsNeglected filovirusesProgress towards the treatment of Ebola haemorrhagic fever.Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirusEnhanced protection against Ebola virus mediated by an improved adenovirus-based vaccinePossible leap ahead in filovirus therapeutics.Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Different potential of C-type lectin-mediated entry between Marburg virus strainsAcute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1βTransmission potential and design of adequate control measures for Marburg hemorrhagic feverCross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primatesVesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicineSafety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialSequence variability in viral genome non-coding regions likely contribute to observed differences in viral replication amongst MARV strainsMechanisms of immunity in post-exposure vaccination against Ebola virus infection.Antibody-dependent enhancement of Marburg virus infectionAdvances in virus-like particle vaccines for filoviruses.A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks.Clinical aspects of Marburg hemorrhagic feverRecombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infectionsFilovirus vaccines.Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease.
P2860
Q21090120-AF847671-692D-4310-BBDA-5122324FBEC9Q21131118-F810F0FB-F6E8-4E9F-9C97-0146F1BBF2C3Q21131585-66F50662-2042-4442-ADD3-424D12FF3C65Q21131616-192B924F-4834-4914-A3AF-CA73A6075E84Q21245136-7F390D1E-9416-4195-97E6-AD6219F8943EQ21534720-5446210D-498D-4E4E-A37A-5CDC106B0823Q21559476-C406A9F8-28D1-4897-94C3-393E84C5085BQ26798860-48F66D4C-ACCF-46F6-B4FD-556467204231Q26823831-9C7D42FA-8B7D-4E4D-969C-08A5A6FC7337Q27011569-9F395133-41FE-49FC-A531-1D02F69BB650Q27015752-900F40EA-218B-409B-BB54-7B50360735CBQ27303778-DE838C04-8518-4C6B-B440-CAF3D8FEB7F9Q27485491-34612AEB-74B6-484D-B1F7-E420B325A241Q28383265-0E33FB44-067A-4EE1-82A6-D4D00187476CQ30230272-741972D1-76B0-4B5D-8135-4F72CEBC18C0Q30724121-FEF953CE-6FBE-43B3-B5B0-789EF6BF6687Q33434415-9E4007CA-D212-4004-B324-3C5B78364528Q33701830-AC314A04-1D8F-4CB1-B685-3F3A0881B095Q33713083-91528958-61AB-40CF-BAFC-FBC6537A3FD6Q33721746-4E600CAF-9180-4B50-BCAE-00533C4D3DF8Q33818337-F764E463-02F4-46D4-A782-ECC684A878A1Q33826885-8A88B4B2-3688-4345-B82A-B1BF0ACE554FQ34441577-26759ED8-DD27-44C6-8026-014F39720EE2Q34515978-BF02CD2C-8D48-43CE-A4CB-D3B24E190B35Q34566171-F4600F5E-8050-4906-A09B-260AAAEB33ADQ34589949-3D6888F6-8718-4EA5-BC4D-4C40058AAAE8Q34598925-609B2AFB-363B-4BD4-B81C-250533809ACAQ34606818-8BA8F5D6-3393-4044-8837-75031ED33DCDQ34761889-086045CF-CBE7-4786-A771-D3161CCD4A13Q35048254-2718FC47-C082-4CEF-9A42-7221C96B7B52Q35055198-A57E3AB1-AD67-494D-B94C-71B7BAB53B03Q35077488-90895BB3-E13D-4260-84BC-EE33761FAFFFQ35192417-894F3A86-C639-4F58-BBF5-744D7FC32AA1Q35299989-11D4D260-BFD5-4060-B29C-48CFFD80ADE2Q35300029-1963D5FD-2116-4F17-ABCF-9AA22228FBDCQ35363479-FDC3B2AC-D3BC-49F1-A9F9-32AFF4372715Q35446144-617A4AE6-5FB6-4A33-B5A0-3512A7E52329Q35557184-54E3994F-971E-45C8-AFC5-C59D94BE1836Q35558539-1E17217E-90FC-43C1-B6EC-B6B952DA1718Q35613127-9CC5737A-A6E8-40CB-89CB-CD60146ECFAA
P2860
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Postexposure protection agains ...... mates: an efficacy assessment.
@ast
Postexposure protection agains ...... mates: an efficacy assessment.
@en
Postexposure protection agains ...... mates: an efficacy assessment.
@nl
type
label
Postexposure protection agains ...... mates: an efficacy assessment.
@ast
Postexposure protection agains ...... mates: an efficacy assessment.
@en
Postexposure protection agains ...... mates: an efficacy assessment.
@nl
prefLabel
Postexposure protection agains ...... mates: an efficacy assessment.
@ast
Postexposure protection agains ...... mates: an efficacy assessment.
@en
Postexposure protection agains ...... mates: an efficacy assessment.
@nl
P2093
P50
P1433
P1476
Postexposure protection agains ...... mates: an efficacy assessment.
@en
P2093
Elizabeth A Fritz
Elliott Kagan
Joan B Geisbert
Lisa Fernando
Steven M Jones
P304
P356
10.1016/S0140-6736(06)68546-2
P407
P50
P577
2006-04-01T00:00:00Z